

Method for Comparing Percutaneous Absorption of Steroids

Archives of Dermatology

86, 608

DOI: 10.1001/archderm.1962.01590110044005

Citation Report

#	ARTICLE	IF	CITATIONS
1	Percutaneous Absorption. Current Problems in Dermatology, 1973, 5, 1-36.	0.7	13
2	Human Models. , 1992, , 17-25.		1
3	Percutaneous Absorption of Steroids. Archives of Dermatology, 1962, 86, 611.	1.4	185
4	HISTOLOGICAL CHANGES IN PSORIASIS TREATED WITH TOPICAL FLUOCINOLONE AND OCCLUSION.. British Journal of Dermatology, 1963, 75, 434-440.	1.5	20
5	The Effect of Temperature and Humidity on the Penetration of C14 Acetylsalicylic Acid in Excised Human Skin. Journal of Investigative Dermatology, 1963, 41, 307-311.	0.7	41
6	Cutaneous Changes Following Local Injection of Triamcinolone. Archives of Dermatology, 1963, 88, 820.	1.4	68
7	A Hazard of Plastic Film Therapy. Archives of Dermatology, 1963, 87, 633.	1.4	13
8	Existence of Reservoir in the Stratum Corneum. Archives of Dermatology, 1963, 88, 20.	1.4	230
9	Topical Activities of Betamethasone Esters in Man. Archives of Dermatology, 1964, 89, 741.	1.4	117
10	Influence of Dimethylsulfoxide (DMSO). Archives of Dermatology, 1964, 90, 512.	1.4	217
11	Acne Treated With Compress and a Corticosteroid Cream. Archives of Dermatology, 1964, 89, 141.	1.4	5
12	Plasma Cortisol Suppression by Steroid Creams. Archives of Dermatology, 1964, 89, 734.	1.4	67
13	Effect of Topical Fluorometholone on Infected and Uninfected Dermatoses. Archives of Dermatology, 1964, 90, 604.	1.4	2
14	The Physiological Disposition of C14-Norepinephrine in Patients with Atopic Dermatitis and Other Dermatoses**From the Department of Dermatology of the Graduate School of Medicine, The Graduate Hospital and the Bockus Research Institute of the University of Pennsylvania and the Department of Radiology of The Graduate Hospital, University of Pennsylvania, Philadelphia, Penna.. Journal of Investigative Dermatology, 1964, 43, 193-200.	0.7	35
15	Topical Suppression of Eccrine Sweat Delivery with a New Anticholinergic Agent. Journal of Investigative Dermatology, 1964, 42, 151-155.	0.7	32
16	BETAMETHASONE 17-VALERATE: A NEW TOPICAL CORTICOSTEROID. Lancet, The, 1964, 283, 1177-1179.	13.7	49
17	Comparative Efficacy of Topical Anti-inflammatory Corticosteroids. Journal of Pharmaceutical Sciences, 1965, 54, 335-354.	3.3	42
18	Factors Influencing Percutaneous Absorption II. Journal of Pharmaceutical Sciences, 1965, 54, 554-556.	3.3	28

#	ARTICLE	IF	CITATIONS
19	Percutaneous Corticosteroid Absorption Correlated to Partition Coefficient. Journal of Pharmaceutical Sciences, 1965, 54, 591-594.	3.3	65
20	Investigation of Some Factors Influencing Percutaneous Absorption III. Journal of Pharmaceutical Sciences, 1965, 54, 1281-1284.	3.3	20
21	Studies in the Mechanism of Steroid Vasoconstriction*. Journal of Investigative Dermatology, 1965, 44, 129-131.	0.7	26
22	An in vitro Study of the Relative Moisture Occlusive Properties of Several Topical Vehicles and Saran Wrap®**From the Department of Pharmaceutical Research and Development, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania.. Journal of Investigative Dermatology, 1965, 44, 361-363.	0.7	21
23	THE ROLE OF VEHICLES IN THE PERCUTANEOUS ABSORPTION OF CORTICOSTEROIDS... British Journal of Dermatology, 1965, 77, 569-575.	1.5	75
24	THE EFFECT OF FORMULATION ON THE CLINICAL RESPONSE TO TOPICAL FLUOCINOLONE ACETONIDE.. British Journal of Dermatology, 1965, 77, 579-581.	1.5	17
25	A COMPARISON OF 0.1% BETAMETHASONE VALERATE AND 0.1% FLUOCINOLONE ACETONIDE IN THE TREATMENT OF PSORIASIS.. British Journal of Dermatology, 1965, 77, 590-592.	1.5	1
26	Percutaneous Absorption of Corticosteroids. New England Journal of Medicine, 1965, 273, 831-840.	27.0	102
27	Dimethylsulfoxide (DMSO) Induction of a Steroid Reservoir in Human Skin. Archives of Dermatology, 1965, 91, 657.	1.4	98
28	Percutaneous Absorption. Archives of Environmental Health, 1965, 11, 551-554.	0.4	15
29	Topical Pharmacology and Toxicology of Dimethyl Sulfoxideâ€”Part 1. JAMA - Journal of the American Medical Association, 1965, 193, 796.	7.4	283
30	Percutaneous absorption. Toxicology and Applied Pharmacology, 1965, 7, 1-6.	2.8	44
31	Ist der Vasoconstrictionstest zum Vergleich der Wirkungsstärke 1/2rtlich applizierter Corticosteroide geeignet?. Archives of Dermatological Research, 1966, 226, 359-368.	1.9	11
32	Comparison of steroids by vasoconstriction.. British Journal of Dermatology, 1966, 78, 182-183.	1.5	15
33	Mediators of Inflammation. Archives of Dermatology, 1966, 93, 601.	1.4	2
34	Corticosteroid Reservoir in the Stratum Corneum. Archives of Dermatology, 1966, 94, 81.	1.4	17
35	Percutaneous Absorption of Hydrocortisone in Children. JAMA Pediatrics, 1966, 112, 218.	3.0	20
36	Betamethasone 17-Valerate. Archives of Dermatology, 1967, 95, 514.	1.4	3

#	ARTICLE	IF	CITATIONS
37	THE EFFECT ON ADRENAL FUNCTION OF TREATMENT OF ECZEMA AND PSORIASIS WITH TRIAMCINOLONE ACETONIDE. British Journal of Dermatology, 1967, 79, 475-486.	1.5	25
38	Effect of Corticosteroids on Isolated Vascular Smooth Muscle**From the Mayo Clinic and Mayo Foundation: Section of Dermatology, Rochester, Minn.. Journal of Investigative Dermatology, 1967, 49, 519-525.	0.7	16
40	THE ASSESSMENT OF FOUR NEW FLUOCORTOLONE ANALOGUES BY A MODIFIED VASOCONSTRICTION ASSAY. British Journal of Dermatology, 1968, 80, 46-53.	1.5	16
41	CLINICAL EVALUATION OF A NEW TOPICAL CORTICOSTEROID BECLOMETHASONE DIPROPIONATE. British Journal of Dermatology, 1968, 80, 111-117.	1.5	31
42	TOPICAL CORTICOSTEROIDS—AN EXPERIMENTAL EVALUATION OF THE VASOCONSTRICTOR TEST AS AN INDEX OF ANTI-INFLAMMATORY ACTIVITY. British Journal of Dermatology, 1968, 80, 328-336.	1.5	37
43	RELEASE OF BETAMETHASONE DERIVATIVES FROM OINTMENTS—IN VIVO AND IN VITRO STUDIES. British Journal of Dermatology, 1969, 81, 103-112.	1.5	63
44	Distribution of 3H-Betamethasone-17-Valerate After Topical Application in the Domestic Pig**From the Department of Pharmacology, University of Ottawa, Ottawa, Ontario, Canada.. Journal of Investigative Dermatology, 1969, 53, 270-274.	0.7	5
45	Percutaneous Steroid Absorption in Anhidrosis**From the Department of Dermatology, College of Medicine, University of Illinois, and Hines Veterans Administration Hospital, Hines, Illinois.. Journal of Investigative Dermatology, 1969, 53, 454-457.	0.7	6
47	Percutaneous Absorption of Steroids*. Journal of Investigative Dermatology, 1969, 52, 63-70.	0.7	325
48	Enhancement of percutaneous absorption by the use of volatile: Nonvolatile systems as vehicles. Journal of Pharmaceutical Sciences, 1969, 58, 1098-1102.	3.3	150
49	EFFECT OF PLASTIC OCCLUSIVE DRESSINGS ON PSORIATIC EPIDERMIS. British Journal of Dermatology, 1970, 82, 458-462.	1.5	58
50	VASOCONSTRICTOR ACTIVITY OF TOPICAL CORTICOSTEROIDS—METHODODOLOGY AND RESULTS. British Journal of Dermatology, 1970, 82, 86-86.	1.5	56
51	Modified Granuloma Pouch Procedure for the Evaluation of Topically Applied Anti-inflammatory Steroids. Journal of Pharmaceutical Sciences, 1970, 59, 267-270.	3.3	9
52	Beitrag zur Penetrationskinetik topischer Steroide. Archives of Dermatological Research, 1970, 237, 769-773.	1.9	3
53	Quantitative and radioautographic studies on the penetration kinetics of 9?-fluoro-16-methylene-prednisolone-21-acetate-7-T in human skin. Archives of Dermatological Research, 1970, 239, 252-265.	1.9	8
54	Recent Advances in Dermatology. Scottish Medical Journal, 1970, 15, 73-83.	1.3	0
55	Precise Evaluation of Topically Applied Corticosteroid Potency. Archives of Dermatology, 1970, 101, 531.	1.4	62
56	The physical, animal and human pharmacologic, and toxicologic properties of desonide, a new, topically active, antiinflammatory steroid. Toxicology and Applied Pharmacology, 1971, 20, 522-537.	2.8	8

#	ARTICLE	IF	CITATIONS
57	THE ABSORPTION OF TOPICAL CORTICOSTEROIDS, WITH PARTICULAR REFERENCE TO PERCUTANEOUS ABSORPTION IN INFANCY AND CHILDHOOD. Medical Journal of Australia, 1971, 1, 1021-1025.	1.7	16
58	Vehicle Design for a New Tropical Steroid, Fluocinonide. Journal of Investigative Dermatology, 1971, 56, 392-399.	0.7	68
59	Vasoconstrictor Potency of Corticoids: Intradermal Injection. Journal of Investigative Dermatology, 1971, 57, 371-376.	0.7	15
60	THE INFLUENCE OF VEHICLE COMPOSITION ON THE VASOCONSTRICTOR ACTIVITY OF BETAMETHASONE IT-BENZOATE. British Journal of Dermatology, 1971, 85, 171-176.	1.5	31
61	THE IN VITRO PENETRATION OF FLUOCINONIDE THROUGH HUMAN SKIN FROM DIFFERENT VOLUMES OF DMSO. British Journal of Dermatology, 1971, 85, 457-461.	1.5	14
62	THE EVALUATION OF A NOVEL CORTICOSTEKOID FORMULATION, FLUOCINONIDE IN "FAPG" BASE, IN THE BLANCHING TEST. British Journal of Dermatology, 1971, 85, 573-576.	1.5	18
63	Penetration der Steroide. Lipid - Fett, 1971, 73, 576-582.	0.4	2
64	Absorption of Drugs through the Skin. , 1971, , 103-174.		34
65	Fluocinonide. Archives of Dermatology, 1971, 104, 632.	1.4	9
66	Bioassay System for Formulations of Topically Applied Glucocorticosteroids. Archives of Dermatology, 1972, 106, 825.	1.4	64
67	Paper-Patch Test for Evaluating Vasoconstrictive Activity of Corticosteroids. Archives of Dermatology, 1972, 105, 856.	1.4	7
68	ROSACEA-LIKE DERMATITIS: CONTRAINDICATION OR INTOLERANCE, REACTION TO STRONG STEROIDS. British Journal of Dermatology, 1972, 86, 253-259.	1.5	65
69	RECENT PROGRESS IN THE FORMULATION OF VEHICLES FOR TOPICAL APPLICATIONS. British Journal of Dermatology, 1972, 87, 386-389.	1.5	15
70	Ergebnisse reflexphotometrischer bestimmungen der vasoconstriction nach topischer steroidapplikation methode, aussagekraft, fehlerquellen. Archives of Dermatological Research, 1973, 247, 379-386.	1.9	16
71	Penetrationskinetik von radiomarkiertem Hydrocortison aus verschiedenen Salbengrundlagen in die menschliche Haut ? in vitro. Archives of Dermatological Research, 1973, 246, 335-354.	1.9	23
72	Corticosteroid-Induced Vasoconstriction Studied by Xenon 133 Clearance. Journal of Investigative Dermatology, 1973, 61, 242-244.	0.7	21
73	BRITISH ALLERGY SOCIETY. Clinical and Experimental Allergy, 1973, 3, 235-235.	2.9	1
75	Topical Corticosteroids. Medical Clinics of North America, 1973, 57, 1253-1264.	2.5	37

#	ARTICLE	IF	CITATIONS
76	Der Hautvasokonstriktionstest am Menschen als Prüfmethode für Externkortikoide. <i>Dermatology</i> , 1973, 147, 353-375.	2.1	8
77	Paired Comparison Vasoconstrictor Assays. <i>Archives of Dermatology</i> , 1974, 109, 367.	1.4	9
78	Various Vagaries of Vasoconstriction. <i>Archives of Dermatology</i> , 1974, 110, 238.	1.4	18
79	Bewertung von corticoid-externa im iontophorese-test. <i>Archives of Dermatological Research</i> , 1974, 250, 369-380.	1.9	2
80	Ergebnisse reflexionsphotometrischer Bestimmungen der Vasoconstriction nach topischer Steroidapplikation. <i>Archives of Dermatological Research</i> , 1974, 248, 387-390.	1.9	6
81	Development and evaluation of ointment and cream vehicles for a new topical steroid, fluclorolone acetone. <i>British Journal of Dermatology</i> , 1974, 90, 187-195.	1.5	20
82	The clinical evaluation of a new topical corticosteroid, clobetasol propionate.. <i>British Journal of Dermatology</i> , 1974, 90, 197-203.	1.5	47
83	Assay of Topical Corticosteroids by Suppression of Experimental Inflammation in Humans. <i>Journal of Investigative Dermatology</i> , 1974, 63, 292-297.	0.7	38
84	Der Hautvasokonstriktionstest am Menschen als Prüfmethode für Externkortikoide. <i>Dermatology</i> , 1974, 148, 160-174.	2.1	5
85	A Comparison of Metosyn and Betnovate in the Treatment of Eczema and Psoriasis. <i>Journal of International Medical Research</i> , 1974, 2, 71-75.	1.0	2
86	Betamethasone Dipropionate (Diprosone): A New Topical Steroid. A Multinational, Multicenter Evaluation. <i>Journal of International Medical Research</i> , 1975, 3, 275-278.	1.0	6
87	Evaluation des corticostéroïdes topiques. <i>Dermatology</i> , 1975, 151, 168-176.	2.1	1
88	Percutaneous Absorption. <i>Journal of Pharmaceutical Sciences</i> , 1975, 64, 901-924.	3.3	190
89	THE MODERN TOPICAL STEROID. <i>International Journal of Dermatology</i> , 1975, 14, 412-421.	1.0	11
90	Intranasal betamethasone valerate in the treatment of seasonal rhinitis. <i>Clinical and Experimental Allergy</i> , 1975, 5, 285-290.	2.9	9
91	Vasoconstrictor Activities of some Novel Synthetic Steroids in Alcoholic Solution. <i>Journal of Investigative Dermatology</i> , 1975, 64, 418-422.	0.7	11
92	Effect Of Fluocinolone Acetonide Cream On Human Skin Blood Flow. <i>Journal of Investigative Dermatology</i> , 1975, 65, 241-243.	0.7	13
93	PERCUTANEOUS ABSORPTION, VEHICLES AND DERMATOLOGICAL PRESCRIBING. <i>Australasian Journal of Dermatology</i> , 1975, 16, 60-78.	0.7	4

#	ARTICLE	IF	CITATIONS
94	Double-Blind Comparison of Halcinonide and Betamethasone Valerate. Archives of Dermatology, 1975, 111, 731.	1.4	4
95	Tachyphylaxis to the Action of Topically Applied Corticosteroids. Archives of Dermatology, 1975, 111, 581.	1.4	99
96	An a-nor-3-thia-5 ¹² -pregnane. Steroids, 1975, 26, 359-362.	1.8	5
97	Local effects of topically applied steroids. The Journal of Steroid Biochemistry, 1975, 6, 717-721.	1.1	5
98	Clinical Use of Topical Corticosteroids. Drugs, 1976, 11, 193-199.	10.9	24
99	Halcinonide, a New Topical Anti-Inflammatory Steroid. Journal of International Medical Research, 1976, 4, 34-36.	1.0	2
100	A Comparative Clinical Evaluation of a New Topical Steroid "Halcinonide" and Hydrocortisone in Steroid-Responsive Dermatoses. Journal of International Medical Research, 1976, 4, 228-231.	1.0	7
101	Acute tolerance to effects of topical glucocorticosteroids. British Journal of Dermatology, 1976, 94, 25-31.	1.5	36
102	The clinical assessment of topical corticosteroid activity. British Journal of Dermatology, 1976, 94, 33-41.	1.5	40
103	The relationship between the course of psoriasis and transepidermal water loss, photoelectric plethysmography and reflex photometry. British Journal of Dermatology, 1976, 94, 253-261.	1.5	16
104	THE MOUSE TAIL TEST FOR EVALUATION OF TOPICALLY APPLIED CORTICOSTEROIDS. International Journal of Dermatology, 1976, 15, 515-516.	1.0	2
107	Diflorasone Diacetate: Vasoconstrictor Activity and Clinical Efficacy of a New Topical Corticosteroid. Journal of International Medical Research, 1976, 4, 454-461.	1.0	20
108	Dependence of Corticosteroid Penetration on the Vehicle. Archives of Dermatology, 1976, 112, 675.	1.4	39
109	Betamethasone Dipropionate Cream For the Treatment of Psoriasis. Archives of Dermatology, 1976, 112, 681.	1.4	7
110	The Development of Semi-Solid Dosage Forms: An Overview. Drug Development and Industrial Pharmacy, 1976, 2, 325-357.	0.1	1
111	Inhibition of Induction of Human Contact Sensitization by Topical Glucocorticosteroids. Archives of Dermatology, 1976, 112, 175.	1.4	15
112	Comparison of 0.1 % Halcinonide with 0.05 % Betamethasone Dipropionate in the Treatment of Acute and Chronic Dermatoses. Current Medical Research and Opinion, 1977, 5, 328-332.	1.9	2
113	Therapeutic Uses of Halcinonide. Scottish Medical Journal, 1977, 22, 231-233.	1.3	2

#	ARTICLE	IF	CITATIONS
114	A Clinical Comparison of Betamethasone 17,21-Dipropionate and Clobetasol Propionate Creams in Dermatology. Journal of International Medical Research, 1977, 5, 128-131.	1.0	5
115	Environmental Temperature and The Percutaneous Absorption of a Cholinesterase Inhibitor, Vx. Journal of Investigative Dermatology, 1977, 68, 357-361.	0.7	56
117	A double-blind trial of 0.05% clobetasol proprionate in the treatment of vitiligo. British Journal of Dermatology, 1977, 96, 71-73.	1.5	62
118	Essential fatty acid deficient hairless mouse: the effects of topical agents on the epidermis. British Journal of Dermatology, 1977, 97, 39-47.	1.5	16
119	ASSESSMENT OF TOPICAL ANTI-INFLAMMATORY ACTIVITY IN RATS WITH CANTHARIDIN-INDUCED INFLAMMATION. Journal of Investigative Dermatology, 1977, 68, 161-164.	0.7	14
120	STUDIES ON 133XE WASH-OUT FROM HUMAN SKIN: QUANTITATIVE MEASUREMENTS OF BLOOD FLOW IN NORMAL AND CORTICOSTEROID-TREATED SKIN. Journal of Investigative Dermatology, 1977, 68, 196-200.	0.7	20
121	New experimental model for the primary evaluation of topical contra-inflammatory agents. Archives of Dermatological Research, 1977, 259, 141-149.	1.9	12
122	Results of reflex photometric determinations of vasoconstriction after topical steroid application. Archives of Dermatological Research, 1977, 257, 281-285.	1.9	8
123	Comparative study of the vasoconstrictor activity of halopredone acetate in a modified McKenzie test. European Journal of Clinical Pharmacology, 1978, 14, 325-329.	1.9	2
124	Percutaneous Absorption and Excretion of Tritium-Labeled Diflorasone Diacetate, a New Topical Corticosteroid in the Rat, Monkey and Man. Journal of Investigative Dermatology, 1978, 71, 372-377.	0.7	39
125	Effects of corticosteroids on the growth and metabolism of fibroblasts cultured from human skin. British Journal of Dermatology, 1978, 99, 253-261.	1.5	40
126	SYSTEMIC REACTIONS TO TOPICALLY APPLIED DRUGS. International Journal of Dermatology, 1978, 17, 768-775.	1.0	24
127	ACTIVITY AND BIOAVAILABILITY OF TOPICAL STEROIDS. IN VIVO / IN VITRO CORRELATIONS FOR THE VASOCONSTRICTOR TEST. Journal of Clinical Pharmacy and Therapeutics, 1978, 3, 43-65.	1.5	22
128	Skin Levels and Vasoconstrictor Assay of Topically Applied Hydrocortisone. Archives of Dermatology, 1979, 115, 440.	1.4	9
129	Externa-Trãgerstoffe und Wirkstoffverfã¼gbarkeit in der Haut. Lipid - Fett, 1979, 81, 43-45.	0.4	0
130	Percutaneous Nitroglycerin Absorption in Rats. Journal of Pharmaceutical Sciences, 1979, 68, 608-612.	3.3	21
131	Penetration of various corticosteroids through epidermis in vitro. Archives of Dermatological Research, 1979, 265, 101-104.	1.9	15
132	Skin irritancy testing of toiletries and cosmetics on novel human models. International Journal of Cosmetic Science, 1979, 1, 363-366.	2.6	4

#	ARTICLE	IF	CITATIONS
133	The effect of various corticosteroids on the release of β -glucuronidase from human leukocytes challenged with zymosan. British Journal of Dermatology, 1979, 101, 553-556.	1.5	0
134	The epidermal reservoir; A theoretical approach. International Journal of Pharmaceutics, 1979, 2, 265-274.	5.2	60
135	A Double-Blind Controlled Trial of Betamethasone Dipropionate 0.05% (Diprosone®) in Comparison with Fluocinolone Acetonide 0.025% (Synalar®) in Psoriasis and other Steroid-Responsive Dermatoses. Journal of International Medical Research, 1979, 7, 411-414.	1.0	3
136	Halcinonide. Analytical Profiles of Drug Substances, 1979, , 251-281.	0.0	3
137	The use and Abuse of Topical Corticosteroids in Dermatology. Scottish Medical Journal, 1980, 25, 287-291.	1.3	5
138	Epidermal thinning: Evaluation of commercial corticosteroids. Archives of Dermatological Research, 1980, 267, 7-24.	1.9	9
139	Hydration and Percutaneous Absorption: I. Influence of Hydration on Alkanol Permeation Through Hairless Mouse Skin. Journal of Investigative Dermatology, 1980, 75, 346-352.	0.7	120
140	The chamber vasoconstrictor assay. i. comparison with occluded and unoccluded tests using four corticosteroids. Clinical and Experimental Dermatology, 1980, 5, 191-196.	1.3	8
142	The human vasoconstrictor assay for topical steroids. Journal of Pharmacological Methods, 1980, 4, 209-220.	0.7	11
143	Topical Corticosteroids. Drugs, 1980, 19, 119-134.	10.9	99
144	Use of glucocorticosteroids in psoriasis. , 1980, 11, 497-508.		12
145	Theoretical aspects of metabolism in the epidermis. International Journal of Pharmaceutics, 1980, 4, 229-239.	5.2	43
146	MECHANISM OF ANTI-INFLAMMATORY ACTION OF GLUCOCORTICOIDS: RE-EVALUATION OF VASCULAR CONSTRICTION HYPOTHESIS. British Journal of Pharmacology, 1981, 73, 605-608.	5.4	20
147	The Effects of Increased Penetration of Betamethasone Dipropionate in a Propylene Glycol Base (Diprolene) for Psoriasis. Journal of International Medical Research, 1981, 9, 128-131.	1.0	5
149	Topical Steroids. International Journal of Dermatology, 1981, 20, 632-641.	1.0	13
150	THE EFFECT OF BETAMETHASONE DIPROPIONATE GLYCOL OINTMENT 0.05% (DIPROSONE O.V.) ON ADRENOCORTICAL FUNCTION. Australasian Journal of Dermatology, 1981, 22, 113-118.	0.7	2
151	Endocrine complications of topical and intralesional corticosteroid therapy.. Archives of Disease in Childhood, 1982, 57, 204-207.	1.9	39
152	Steroid-Induced Vasoconstriction: Glucocorticoid Antagonist Studies. Journal of Clinical Endocrinology and Metabolism, 1982, 54, 1075-1077.	3.6	81

#	ARTICLE	IF	CITATIONS
153	Anti-inflammatory steroids without pituitary-adrenal suppression. <i>Science</i> , 1982, 215, 989-991.	12.6	100
154	Comparison of Diflorasone Diacetate and Betamethasone Dipropionate Ointment in the Treatment of Psoriasis. <i>Journal of International Medical Research</i> , 1982, 10, 22-27.	1.0	5
155	PENETRATION OF TOPICAL CORTICOSTEROIDS THROUGH HUMAN EPIDERMIS. <i>Journal of Dermatology</i> , 1982, 9, 45-58.	1.2	10
156	Soft drugs 4. 3-Spirothiazolidines of hydrocortisone and its derivatives. <i>International Journal of Pharmaceutics</i> , 1982, 10, 307-321.	5.2	33
157	Percutaneous metabolism with saturable enzyme kinetics. <i>International Journal of Pharmaceutics</i> , 1982, 11, 187-197.	5.2	39
158	A pharmacokinetic model for percutaneous absorption. <i>International Journal of Pharmaceutics</i> , 1982, 11, 119-129.	5.2	101
159	Iatrogenic hyperadrenocorticism during topical steroid therapy: Assessment of systemic effects by metabolic criteria. <i>Journal of the American Academy of Dermatology</i> , 1982, 6, 1054-1060.	1.2	17
160	Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. <i>European Journal of Clinical Pharmacology</i> , 1982, 22, 523-529.	1.9	140
161	Topical Corticosteroids. <i>International Journal of Dermatology</i> , 1982, 21, 59-67.	1.0	45
162	The Effect of Topical Fluocinonide Ointment on Phototherapy of Psoriasis. <i>Journal of Investigative Dermatology</i> , 1982, 78, 157-159.	0.7	29
163	The Effect of Epicutaneous Glucocorticosteroids on Human Monocyte and Neutrophil Migration in Vivo. <i>Journal of Investigative Dermatology</i> , 1982, 78, 386-390.	0.7	18
164	Optimization of Bioavailability of Topical Steroids: Thermodynamic Control. <i>Journal of Investigative Dermatology</i> , 1982, 79, 388-391.	0.7	40
165	Preliminary skin blood flow measurements appear unsuccessful for assessing topical corticosteroid effect. <i>Archives of Dermatological Research</i> , 1983, 275, 419-420.	1.9	32
166	Drug Delivery to Local Subcutaneous Structures Following Topical Administration. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 1375-1380.	3.3	47
167	A Biological Brief on Percutaneous Absorption. <i>Drug Development and Industrial Pharmacy</i> , 1983, 9, 521-560.	2.0	50
168	Percutaneous absorption: possibilities and problems. <i>International Journal of Pharmaceutics</i> , 1983, 16, 255-270.	5.2	30
169	Improved delivery through biological membranes. XII. The effect of the incorporation of biphasic solubilizing groups into prodrugs of steroids. <i>International Journal of Pharmaceutics</i> , 1983, 15, 235-250.	5.2	9
170	Vascular effects of glucocorticosteroids, with special reference to budesonide. <i>General Pharmacology</i> , 1983, 14, 125-127.	0.7	4

#	ARTICLE	IF	CITATIONS
171	Cutaneous Pharmacokinetics: 10 Steps to Percutaneous Absorption. Drug Metabolism Reviews, 1983, 14, 169-205.	3.6	238
172	Azone®: A New Non-Toxic Enhancer of Cutaneous Penetration. Drug Development and Industrial Pharmacy, 1983, 9, 725-744.	2.0	135
173	The Use of Topical Steroids in Psoriasis. Dermatologic Clinics, 1984, 2, 397-409.	1.7	37
174	Treatment of Severe or Resistant Corticosteroid-Responsive Dermatoses with Diprolene® Cream. Journal of International Medical Research, 1984, 12, 163-169.	1.0	6
175	Vasoconstrictor and the anti-inflammatory effects of 7 corticosteroids. Contact Dermatitis, 1984, 11, 108-111.	1.4	7
176	Prediction of Drug Disposition Kinetics in Skin and Plasma Following Topical Administration. Journal of Pharmaceutical Sciences, 1984, 73, 883-887.	3.3	37
177	Assessment of topical corticosteroid preparations: the human skin blanching assay. International Journal of Pharmaceutics, 1984, 19, 245-262.	5.2	55
178	Hydrocortisone. American Pharmacy, 1985, 25, 42-45.	0.2	1
179	A theoretical consideration of percutaneous drug absorption. Journal of Pharmacokinetics and Pharmacodynamics, 1985, 13, 55-72.	0.6	28
180	RU 486 Inhibits Peripheral Effects of Glucocorticoids in Humans*. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 1009-1011.	3.6	92
181	Cutaneous biotransformation as a parameter in the modulation of the activity of topical corticosteroids. International Journal of Pharmaceutics, 1985, 26, 175-189.	5.2	34
182	The prediction of plasma levels of drugs following transdermal application. Journal of Controlled Release, 1985, 1, 177-182.	9.9	35
183	Release of sorbic acid from ointment bases. International Journal of Pharmaceutics, 1986, 28, 113-117.	5.2	4
184	Topical clobetasol-17-propionate: Review of its clinical efficacy and safety. Journal of the American Academy of Dermatology, 1986, 15, 246-255.	1.2	72
185	A calculation of percutaneous drug absorption—II. Computation results. Computers in Biology and Medicine, 1986, 16, 21-37.	7.0	19
186	Regional variation in percutaneous absorption in man: measurement by the stripping method. Archives of Dermatological Research, 1986, 278, 465-469.	1.9	126
187	A New Technique for Ranking Vascular Corticosteroid Effects in Humans Using Laser-Doppler Velocimetry. Journal of Investigative Dermatology, 1986, 86, 275-278.	0.7	37
188	Tachyphylaxis to Topical Steroid Measured by Histamine-induced Wheal Suppression. International Journal of Dermatology, 1986, 25, 324-327.	1.0	43

#	ARTICLE	IF	CITATIONS
189	The bioavailability of dermatological and other topically administered drugs. Pharmaceutical Research, 1986, 03, 253-262.	3.5	26
191	Are Generic Formulations Equivalent to Trade Name Topical Glucocorticoids?. Archives of Dermatology, 1987, 123, 1312.	1.4	73
192	Studies on benzyl acetate. III. The percutaneous absorption and disposition of [Methylene-14C]benzyl acetate in the rat. Food and Chemical Toxicology, 1987, 25, 521-525.	3.6	26
193	Topical Corticosteroids. Journal of Pharmacy Technology, 1987, 3, 56-60.	1.0	5
194	Measurement of the Stratum Corneum Drug Reservoir to Predict the Therapeutic Efficacy of Topical Iododeoxyuridine for Herpes Simplex Virus Infection. Journal of Investigative Dermatology, 1987, 89, 598-602.	0.7	35
195	Atopic Dermatitis Revisited. International Journal of Dermatology, 1987, 26, 139-149.	1.0	17
196	Psoriasis. British Journal of Dermatology, 1988, 119, 445-461.	1.5	160
197	Clinical Pharmacology and Pharmacokinetic Properties of Topically Applied Corticosteroids. Drugs, 1988, 36, 51-61.	10.9	45
198	Topical intranasal corticosteroid therapy in rhinitis. Journal of Allergy and Clinical Immunology, 1988, 81, 984-991.	2.9	81
199	Comparison of the blanching activities of Dermovate, Betnovate and Eumovate creams and ointments. International Journal of Pharmaceutics, 1988, 41, 63-66.	5.2	16
200	Side Effects of Topical Corticosteroids and their Prevention. Drugs, 1988, 36, 15-23.	10.9	56
201	A pharmacokinetic model for percutaneous absorption of valproic acid and prediction of drug disposition.. Journal of Pharmacobio-dynamics, 1988, 11, 444-452.	0.5	10
202	Flexible Classification for the Clinical Potency of Topical Corticosteroid Proprieties. Drug Intelligence & Clinical Pharmacy, 1988, 22, 412-415.	0.4	3
203	The Use and Abuse of 0.05 Per Cent Clobetasol Propionate in Dermatology. Dermatologic Clinics, 1988, 6, 643-648.	1.7	9
204	Studies on the metabolic fate of S-3460. (I). Absorption, distribution and excretion in rats, rabbits, mice and dogs.. Drug Metabolism and Pharmacokinetics, 1988, 3, 41-60.	0.0	0
205	Percutaneous Absorption: In Vivo Methods in Humans and Animals. Journal of the American College of Toxicology, 1989, 8, 803-813.	0.2	27
206	Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide. Archives of Dermatology, 1989, 125, 1662.	1.4	9
207	Chromatographic determination of percutaneous absorption of topical non-radiolabelled prednisolone in vivo, and preliminary application to transdermal pharmacokinetics. Biomedical Applications, 1989, 493, 373-379.	1.7	4

#	ARTICLE	IF	CITATIONS
208	Transepidermal water loss with and without sweat gland inactivation. Contact Dermatitis, 1989, 21, 16-22.	1.4	44
209	Cutaneous reactive hyperaemia: racial differences induced by corticoid application. British Journal of Dermatology, 1989, 120, 787-794.	1.5	42
210	A double-blind comparison of the efficacy of betamethasone dipropionate cream twice daily versus once daily in the treatment of steroid responsive dermatoses. Clinical and Experimental Dermatology, 1989, 14, 32-34.	1.3	17
211	Time-course of corticosteroid-induced blood flow reduction in normal cutaneous tissue-quantitative measurements during 72 h of treatment. Clinical and Experimental Dermatology, 1989, 14, 210-213.	1.3	11
212	Bioequivalence (bioavailability) of generic topical corticosteroids. Journal of the American Academy of Dermatology, 1989, 20, 791-796.	1.2	32
213	Corticosteroids. Clinics in Dermatology, 1989, 7, 80-97.	1.6	39
214	'Vasoconstriction'â€”Skin Blanchingâ€”Assay for Glucocorticoidsâ€”a Critique. Archives of Dermatology, 1989, 125, 1558.	1.4	28
215	Liposome preparations: A step forward in topical drug therapy for skin disease?. Journal of the American Academy of Dermatology, 1989, 21, 1271-1275.	1.2	55
216	Therapeutic implications of corticosteroid formulations. Journal of Dermatological Treatment, 1990, 1, S11-S13.	2.2	3
217	Percutaneous absorption of triamcinolone acetonide from creams with and without AzoneÂ® in humans in vivo. International Journal of Pharmaceutics, 1990, 66, 53-62.	5.2	6
218	New potent topical anti-inflammatory steroids with reduced side effects: Derivatives of steroid-16-carboxy esters. Journal of Pharmaceutical Sciences, 1990, 79, 617-621.	3.3	17
219	The treatment of psoriasis. Medical Journal of Australia, 1990, 152, 153-164.	1.7	11
220	Studies on the Metabolic Fate of Mometasone furoate (MF). (1). Percutaneous Absorption, Distribution, Excretion after Topical Application to Rats and Rabbits.. Drug Metabolism and Pharmacokinetics, 1990, 5, 785-794.	0.0	0
221	Color quantitation through image processing in dermatology. IEEE Transactions on Medical Imaging, 1990, 9, 262-269.	8.9	42
222	Potential of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet, The, 1990, 335, 1060-1063.	13.7	204
223	Correlation between the drug penetration and the blanching effect of topically applied hydrocortisone creams in human beings. Journal of the American Academy of Dermatology, 1990, 23, 458-462.	1.2	57
224	Treatment of hirsutism with the pure antiandrogen flutamide. Journal of the American Academy of Dermatology, 1990, 23, 462-469.	1.2	125
225	Comparison of enzymic activities of tissues lining portals of drug absorption, using the rat as a model. International Journal of Pharmaceutics, 1990, 62, 259-267.	5.2	23

#	ARTICLE	IF	CITATIONS
226	Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respiratory Medicine, 1990, 84, 19-23.	2.9	184
227	Cutaneous vasoconstrictor response to glucocorticoids in asthma. Lancet, The, 1991, 337, 576-580.	13.7	105
228	Surfactant apoprotein-A concentration in sputum for diagnosis of pulmonary alveolar proteinosis. Lancet, The, 1991, 337, 580-582.	13.7	30
229	Soft drugsâ€”10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38, 149-154.	2.5	93
230	Potency Assessment of Topical Corticoids in the Vasoconstrictor Assay and on Tuberculin-Induced Inflammation. Skin Pharmacology and Physiology, 1991, 4, 191-204.	2.5	6
231	Hydrocolloid Dermatological Patches $\frac{1}{2}$ Corticosteroid Combinations. , 1992, , 503-511.		1
233	Hydrocortisone Valerate. , 1992, , 451-461.		0
234	Betamethasone Valerate $\frac{1}{2}$ Valisone $\frac{1}{2}$ $\frac{1}{2}$ Establishment of a New Standard for Topical Corticosteroid Potency. , 1992, , 335-348.		1
235	Accuracy and Reproducibility of the Multiple-Reading Skin Blanching Assay. , 1992, , 65-73.		4
236	Hydrocortisone 17-Butyrate. , 1992, , 435-450.		0
237	Topical Retinoic Acid Does Not Alter the Vasoconstrictive Properties of Topical Corticosteroids in Humans. Dermatology, 1991, 182, 107-111.	2.1	4
238	Quantification of skin-colour changes induced by topical corticosteroid preparations using the Minolta Chroma Meter. British Journal of Dermatology, 1991, 124, 264-270.	1.5	92
239	11 β -Hydroxysteroid dehydrogenase and enzyme-mediated receptor protection: Life after liquorice?. Clinical Endocrinology, 1991, 35, 281-289.	2.4	52
240	The human skin blanching assay for comparing topical corticosteroid availability. Journal of Dermatological Treatment, 1991, 2, 69-72.	2.2	9
242	Corticosteroids and vascular tone: mapping the messenger maze. Clinical Science, 1992, 82, 597-605.	4.3	107
243	Percutaneous Absorption of Drugs. Clinical Pharmacokinetics, 1992, 23, 253-266.	3.5	66
244	Steroid inhibition of oedema formation in the rat skin. British Journal of Pharmacology, 1992, 106, 628-631.	5.4	10
245	A history of significant steroid discoveries and developments originating at the Schering Corporation (USA) since 1948. Steroids, 1992, 57, 617-623.	1.8	38

#	ARTICLE	IF	CITATIONS
246	The use of corticosteroids in dermatological practice. Medical Journal of Australia, 1992, 156, 428-431.	1.7	36
247	NEW APPROACHES TO ASSESS TOPICAL CORTICOSTEROID BIOEQUIVALENCE: PHARMACOKINETIC EVALUATION. International Journal of Dermatology, 1992, 31, 14-20.	1.0	8
248	CLINICAL TRIALS OF TOPICAL CORTICOSTEROIDS IN PSORIASIS: CORRELATIONS WITH THE VASOCONSTRICTOR ASSAY. International Journal of Dermatology, 1992, 31, 38-40.	1.0	31
249	Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching. British Journal of Dermatology, 1992, 127, 379-381.	1.5	16
250	The effect of topical steroids on cutaneous oxygen tension. British Journal of Dermatology, 1992, 126, 502-504.	1.5	0
251	BIOEQUIVALENCE OF TOPICAL CORTICOSTEROIDS: A REGULATORY PERSPECTIVE. International Journal of Dermatology, 1992, 31, 2-5.	1.0	8
252	Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans. International Journal of Pharmaceutics, 1992, 86, 201-210.	5.2	70
253	Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers. European Journal of Clinical Pharmacology, 1992, 43, 157-159.	1.9	10
254	Relationship between In Vivo Skin Blanching and In Vitro Release Rate for Betamethasone Valerate Creams. Journal of Pharmaceutical Sciences, 1992, 81, 104-106.	3.3	27
255	In Vitro Percutaneous Permeation of Betamethasone and Betamethasone 17-Valerate. Journal of Pharmaceutical Sciences, 1993, 82, 1039-1045.	3.3	7
256	Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clinical Pharmacology and Therapeutics, 1993, 54, 448-456.	4.7	45
257	Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clinical and Experimental Dermatology, 1993, 18, 504-506.	1.3	32
258	Topical betamethasone-17-valerate inhibits heat-induced vasodilatation in man. British Journal of Dermatology, 1993, 128, 45-48.	1.5	3
259	The cutaneous corticosteroid vasoconstriction assay: a reflectance spectroscopic and laser-Doppler flowmetric study. British Journal of Dermatology, 1993, 128, 660-665.	1.5	32
260	A corticosteroid, a non-steroidal anti-inflammatory drug and an antihistamine modulate in vivo vascular reactions before and during post-occlusive hyperaemia. British Journal of Dermatology, 1993, 128, 137-142.	1.5	11
261	11 β -hydroxysteroid dehydrogenase isoforms and their implications for blood pressure regulation. European Journal of Clinical Investigation, 1993, 23, 589-601.	3.4	104
262	Assessment of corticosteroid-induced skin blanching: evaluation of the Minolta Chromameter CR200. International Journal of Pharmaceutics, 1993, 94, 211-222.	5.2	29
263	Cellular mechanisms of the steroid-induced vascular responses in the rabbit ear artery. General Pharmacology, 1993, 24, 1155-1162.	0.7	7

#	ARTICLE	IF	CITATIONS
264	Investigations into the mechanism of vasoconstrictor action of the topical steroid betamethasoneâ€”valerate in the rat. British Journal of Pharmacology, 1993, 108, 544-548.	5.4	7
265	Quantitative vasoconstrictor assay for topical corticosteroids: The puzzling case of fluocinolone acetonide. Journal of the American Academy of Dermatology, 1993, 29, 197-202.	1.2	21
266	Assessment of Topical Corticosteroid Bioavailability In Vivo and In Vitro. , 1993, , 351-366.		1
267	Liposomes: A Promising Future for Dermatocosmetology and Clinical Dermatology. Journal of Liposome Research, 1993, 3, 737-751.	3.3	8
268	Decreased Peripheral Glucocorticoid Sensitivity in Alzheimerâ€™s Disease. Gerontology, 1993, 39, 200-206.	2.8	26
269	Use of Reflectance Spectrophotometry in the Human Corticosteroid Skin Blanching Assay. Journal of Clinical Pharmacology, 1993, 33, 707-711.	2.0	2
270	Effect of topical beclomethasone on histamine-induced increases in nasal airflow resistance and secretion in perennial rhinitis. Clinical Otolaryngology, 1993, 18, 285-290.	1.2	6
271	Assessment of Topical Corticosteroid Activity on Experimentally Induced Contact Dermatitis: Echographic Evaluation with Binary Transformation and Image Analysis. Skin Pharmacology and Physiology, 1993, 6, 85-91.	2.5	16
272	Circadian Activity of Topical 0.05% Betamethasone Dipropionate in Human Skin In Vivo. Journal of Investigative Dermatology, 1994, 102, 734-739.	0.7	33
273	Topical formulations of fluocinolone acetonide. European Journal of Clinical Pharmacology, 1994, 46, 71-5.	1.9	17
274	Measurement of Pharmacodynamic Effects of Dexamethasone on Epidermis by Phosphorus Nuclear Magnetic Resonance Spectroscopy in Vitro. Journal of Pharmaceutical Sciences, 1994, 83, 1339-1344.	3.3	11
275	Workshop III Report: Scaleup of Liquid and Semisolid Disperse Systems. Pharmaceutical Research, 1994, 11, 1216-1220.	3.5	5
276	Topical Corticosteroids and Unwanted Local Effects. Drug Safety, 1994, 10, 406-412.	3.2	31
277	The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis. Clinical Otolaryngology, 1995, 20, 204-210.	1.2	12
278	Formulation Factors Affecting Release of Drug from Topical Vehicles. II. Effect of Solubility on in Vitro Delivery of a Series of n-Alkyl p-Aminobenzoates. Journal of Pharmaceutical Sciences, 1995, 84, 673-676.	3.3	13
279	A time correlation study between reflectance spectroscopic cutaneous vasoconstriction and plasma corticosteroid concentration. British Journal of Dermatology, 1995, 132, 59-65.	1.5	4
280	Oestradiol permeation across human skin, silastic and snake skin membranes: The effects of ethanol/water co-solvent systems. International Journal of Pharmaceutics, 1995, 116, 101-112.	5.2	146
281	Topical Corticosteroids. Dermatologic Clinics, 1995, 13, 805-815.	1.7	22

#	ARTICLE	IF	CITATION
282	A Transgenic Mouse Model Provides a Novel Biological Assay of Topical Glucocorticosteroid Potency. Archives of Dermatology, 1995, 131, 1274.	1.4	4
283	Assessment of Topical Corticosteroid-Induced Skin Blanching Response Using the Visual Mckenzie-Stoughton and Colorimetric Methods. Drug Information Journal, 1995, 29, 923-934.	0.5	6
284	Prolonged occlusion in the treatment of psoriasis: A clinical and immunohistologic study. Journal of the American Academy of Dermatology, 1995, 32, 618-622.	1.2	40
285	Methylprednisolone Aceponate. BioDrugs, 1995, 3, 241-253.	0.7	12
286	Allergic contact dermatitis from topical corticosteroid preparations. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 1995, 6, 67-74.	0.4	11
287	A study of white dermographism in atopic dermatitis. Journal of Dermatological Science, 1996, 11, 148-153.	1.9	4
288	A Reappraisal of Topical Steroid Potency. Pediatric Dermatology, 1996, 13, 239-245.	0.9	32
289	Guidelines of care for the use of topical glucocorticosteroids. Journal of the American Academy of Dermatology, 1996, 35, 615-619.	1.2	123
290	Topical Glucocorticoids with Improved Risk-Benefit Ratio. Drug Safety, 1996, 14, 375-385.	3.2	102
291	Percutaneous absorption of three psoralens commonly used in therapy: Effect of skin occlusion (in) Tj ETQq1 1 0.784314 rgBT ₁₄ /Overl	5.2	14
292	Effect of application time of betamethasone-17-valerate 0.1% cream on skin blanching and stratum corneum drug concentration. International Journal of Pharmaceutics, 1996, 140, 51-60.	5.2	16
293	A comparison of techniques to assess skin blanching following the topical application of glucocorticoids. British Journal of Dermatology, 1996, 134, 837-842.	1.5	21
294	Effect of topically applied lipids on surfactant-irritated skin. British Journal of Dermatology, 1996, 134, 215-220.	1.5	84
295	Abnormal glucocorticoid activity in subjects with risk factors for cardiovascular disease. Endocrine Research, 1996, 22, 701-708.	1.2	42
296	The role of occlusion in corticosteroid therapy of psoriasis. Journal of Dermatological Treatment, 1997, 8, 265-269.	2.2	2
297	Fluticasone Propionate Aqueous Nasal Spray in the Treatment of Nasal Polyposis. Annals of Allergy, Asthma and Immunology, 1997, 78, 270-276.	1.0	95
298	Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthmaâˆ™fâˆ™fâˆ™fâˆ™...âˆ™...âˆ™...âˆ™c. Journal of Allergy and Clinical Immunology, 1997, 100, 467-474.	1.9	46
299	Corticosteroids. Clinics in Dermatology, 1997, 15, 715-721.	1.6	64

#	ARTICLE	IF	CITATIONS
300	Corticosteroid therapy. Revue Francaise D'allergologie Et D'immunologie Clinique, 1997, 37, 1139-1143.	0.1	0
302	A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 1-34.	5.7	312
303	The effects of betamethasone derivatives on endotoxin-induced uveitis in guinea pigs. Inflammation Research, 1997, 46, 486-490.	4.0	6
304	The human skin blanching assay for in vivo topical corticosteroid assessment. International Journal of Pharmaceutics, 1997, 152, 179-183.	5.2	16
305	Subepidermal bullous dermatosis due to topical corticosteroid therapy in dogs. Veterinary Dermatology, 1997, 8, 127-131.	1.2	10
306	What causes airway remodelling in asthma?. Clinical and Experimental Allergy, 1998, 28, 534-536.	2.9	13
307	Percutaneous permeation of the meta, ortho and para isomers of N,N-diethyltoluamide. International Journal of Pharmaceutics, 1998, 160, 31-41.	5.2	4
308	Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. Journal of the American Academy of Dermatology, 1998, 39, 226-231.	1.2	55
309	The critical role of the vehicle to therapeutic efficacy and patient compliance. Journal of the American Academy of Dermatology, 1998, 39, S67-S73.	1.2	26
310	Recent developments in respiratory care pharmacology. Journal of Perianesthesia Nursing, 1998, 13, 359-369.	0.7	2
311	Measuring efficacy and safety of different inhaled corticosteroid preparations. Journal of Allergy and Clinical Immunology, 1998, 102, 879-886.	2.9	78
312	Increased Glucocorticoid Activity in Men With Cardiovascular Risk Factors. Hypertension, 1998, 31, 891-895.	2.7	170
313	Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax, 1999, 54, 289-295.	5.6	146
314	Dorsal Skin Reactions of Hairless Dogs to Topical Treatment with Corticosteroids. Toxicologic Pathology, 1999, 27, 528-535.	1.8	32
315	Postural Skin Colour Changes during the Corticosteroid Blanching Assay. Skin Pharmacology and Physiology, 1999, 12, 199-210.	2.5	11
316	The use of glucocorticoids in dermatology. Journal of Dermatological Treatment, 1999, 10, 83-91.	2.2	9
317	Comparing inhaled glucocorticosteroids. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 42-50.	5.7	6
318	Acetone has anti-inflammatory effects on experimental contact reactions. Contact Dermatitis, 1999, 41, 22-29.	1.4	8

#	ARTICLE	IF	CITATIONS
319	Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 346-357.	4.7	30
320	A New Bleaching Protocol for Hyperpigmented Skin Lesions with a High Concentration of All-trans Retinoic Acid Aqueous Gel. <i>Aesthetic Plastic Surgery</i> , 1999, 23, 285-291.	0.9	33
321	Rheumaderm. <i>Advances in Experimental Medicine and Biology</i> , 1999, , .	1.6	3
322	Evaluation of Topical Application of Clobetasol 17-Propionate from Various Cream Bases. <i>Drug Development and Industrial Pharmacy</i> , 1999, 25, 7-14.	2.0	16
323	Examination on Biological Activities and Fates of New Steroids, Steroid-17-yl Methyl Glycolate Derivatives.. <i>Tohoku Journal of Experimental Medicine</i> , 1999, 187, 127-140.	1.2	2
324	Thermal and Spectroscopic Characterization of Interactions between 2-Nonyl-1,3-Dioxolane and Stratum Corneum Components. <i>Journal of Bioactive and Compatible Polymers</i> , 1999, 14, 162-177.	2.1	17
325	An overview of the efficacy of topical corticosteroids in experimental human nickel contact dermatitis. <i>Contact Dermatitis</i> , 2000, 43, 317-321.	1.4	26
326	The Microcirculation and Inflammation: Site of Action for Glucocorticoids. <i>Microcirculation</i> , 2000, 7, 147-161.	1.8	121
327	Efficacy of Calcipotriol Ointment Applied under Hydrocolloid Occlusion in Psoriasis. <i>Dermatology</i> , 2000, 200, 25-30.	2.1	13
328	Thermal Effects of Emollients on Facial Skin in the Cold: Clinical Report. <i>Acta Dermato-Venereologica</i> , 2000, 80, 203-207.	1.3	10
329	Tissue Specificity of Glucocorticoid Sensitivity in Healthy Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3733-3739.	3.6	80
330	Transient Effect of Inhaled Fluticasone on Airway Mucosal Blood Flow in Subjects with and without Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 918-921.	5.6	98
331	Effect of an Inhaled Glucocorticosteroid on Airway Mucosal Blood Flow in Mild Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 293-296.	5.6	65
332	Topical corticosteroids: An update. <i>Current Problems in Dermatology</i> , 2000, 12, 222-225.	0.0	6
333	Qualitative and Quantitative Assessment of the Benefit???Risk Ratio of Medium Potency Topical Corticosteroids In Vitro and In Vivo. <i>BioDrugs</i> , 2000, 13, 267-277.	4.6	35
334	Characterization of molecular transport across human stratum corneum in vivo. <i>Cutaneous and Ocular Toxicology</i> , 2001, 20, 279-301.	0.3	1
335	In vivo methods for percutaneous absorption measurements. <i>Cutaneous and Ocular Toxicology</i> , 2001, 20, 411-422.	0.3	18
336	A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. <i>Clinical Therapeutics</i> , 2001, 23, 1339-1354.	2.5	112

#	ARTICLE	IF	CITATIONS
337	Book review and Erratum. British Journal of Dermatology, 2001, 144, 1099-1099.	1.5	0
338	Acrogeric phenotype in Ehlers-Danlos syndrome type IV attributed to a missense mutation in the COL3A1 gene. British Journal of Dermatology, 2001, 144, 1086-1087.	1.5	10
339	Digital necrosis in a patient with hypereosinophilic syndrome in the absence of cutaneous eosinophilic vasculitis. British Journal of Dermatology, 2001, 144, 1087-1089.	1.5	21
340	Pityriasis rosea: one virus, two viruses, more viruses?. British Journal of Dermatology, 2001, 144, 1090-1090.	1.5	16
341	Trichoblastoma with sebaceous and sweat gland differentiation. British Journal of Dermatology, 2001, 144, 1090-1092.	1.5	13
342	Cutaneous presentation of chronic lymphatic leukaemia and response to ultraviolet B phototherapy. British Journal of Dermatology, 2001, 144, 1092-1093.	1.5	22
343	Scarring molluscum contagiosum in patients with severe atopic dermatitis: report of two cases. British Journal of Dermatology, 2001, 144, 1094-1095.	1.5	15
344	Unregulated use of clobetasol propionate. British Journal of Dermatology, 2001, 144, 1095-1096.	1.5	33
345	Carbon dioxide laser for removal of multiple cutaneous neurofibromas. British Journal of Dermatology, 2001, 144, 1096-1097.	1.5	34
346	Oral terbinafine treatment for toenail onychomycosis. British Journal of Dermatology, 2001, 144, 1098-1099.	1.5	0
347	Oral terbinafine treatment for toenail onychomycosis: reply from authors. British Journal of Dermatology, 2001, 144, 1098-1098.	1.5	0
348	Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: A pilot study. Pediatric Pulmonology, 2001, 32, 115-121.	2.0	39
349	Fluticasone propionate attenuates platelet-activating factor-induced gas exchange defects in mild asthma. European Respiratory Journal, 2002, 19, 872-878.	6.7	17
350	The use of corticosteroids in severe sepsis and acute respiratory distress syndrome. Annals of Medicine, 2002, 34, 582-589.	3.8	30
353	Topical Corticosteroid-Induced Adrenocortical Insufficiency. American Journal of Clinical Dermatology, 2002, 3, 141-147.	6.7	99
354	Topical corticosteroids: unapproved uses, dosages, or indications. Clinics in Dermatology, 2002, 20, 490-492.	1.6	5
355	Quantification of Corticosteroid-Induced Skin Vasoconstriction: Visual Ranking, Chromameter Measurement or Digital Imaging Analysis. Dermatology, 2002, 205, 3-10.	2.1	15
356	Vasoconstrictor response to topical beclomethasone in major depression. Psychoneuroendocrinology, 2002, 27, 475-487.	2.7	13

#	ARTICLE	IF	CITATIONS
357	Comparison of Skin Stripping, in vitro Release, and Skin Blanching Response Methods to Measure Dose Response and Similarity of Triamcinolone Acetonide Cream Strengths from Two Manufactured Sources. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1312-1323.	3.3	40
358	The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 643-647.	1.9	10
359	Deep temperature monitoring using a zero-heat-flow method. <i>Journal of Anesthesia</i> , 2003, 17, 108-115.	1.7	64
360	Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 91, 326-334.	1.0	41
361	Vasoconstrictive effect of topical applied corticosteroids measured by laser doppler imaging and reflectance spectroscopy. <i>Microvascular Research</i> , 2003, 65, 152-159.	2.5	11
362	Pharmacokinetic analysis of the FDA guidance for industryâ€œTopical dermatologic corticosteroids: in vivo bioequivalenceâ€™. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2003, 56, 53-58.	4.3	7
363	The use of corticosteroids and corticosteroid phobia in atopic dermatitis. <i>Clinics in Dermatology</i> , 2003, 21, 193-200.	1.6	104
364	Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. <i>European Respiratory Journal</i> , 2003, 21, 989-993.	6.7	82
365	Glucocorticoid Sensitivity in Humans-Interindividual Differences and Acute Stress Effects. <i>Stress</i> , 2003, 6, 207-222.	1.8	100
366	Acute Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 740-759.	5.6	265
367	Corticosteroids in Sepsis: From Bench to Bedside?. <i>Shock</i> , 2003, 20, 197-207.	2.1	108
368	Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. <i>European Respiratory Journal</i> , 2004, 23, 552-558.	6.7	90
369	Current guidelines applicable for the approval of topically applied dermatological drugs in the EU. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 503-511.	1.9	2
370	Depigmentation ? a rare side effect to intra-articular glucocorticoid treatment. <i>Clinical Rheumatology</i> , 2004, 23, 373-5.	2.2	21
371	Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 315-328.	1.9	12
372	Evaluation of In Vivo Bioequivalence Methodology for Topical Clobetasol 17-Propionate Based on Pharmacodynamic Modeling Using Chinese Skin. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 207-217.	3.3	17
374	Skin barrier function: effect of age, race and inflammatory disease. <i>The International Journal of Essential Oil Therapeutics: Exploring the Bioactivity of Aromatic Plants</i> , 2004, 14, 70-76.	0.7	10
375	Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. <i>Critical Care Medicine</i> , 2004, 32, 1928-1948.	0.9	543

#	ARTICLE	IF	CITATIONS
376	Skin permeation: The years of enlightenment. International Journal of Pharmaceutics, 2005, 305, 2-12.	5.2	120
378	What Does Potency Actually Mean for Inhaled Corticosteroids?. Journal of Asthma, 2005, 42, 409-417.	1.7	1
379	Clinical Potencies of Glucocorticoids: What do we Really Measure?. Current Respiratory Medicine Reviews, 2005, 1, 103-108.	0.2	15
380	Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases. Skin Pharmacology and Physiology, 2005, 18, 3-11.	2.5	26
382	Therapeutic options in the treatment of psoriasis and atopic dermatitis. Journal of the American Academy of Dermatology, 2005, 53, S3-S16.	1.2	57
383	Corticosteroids: Options in the era of steroid-sparing therapy. Journal of the American Academy of Dermatology, 2005, 53, S50-S58.	1.2	130
384	Quel est le traitement des poussées de dermatite atopique de l'enfant ?. Annales De Dermatologie Et De Venereologie, 2005, 132, 193-224.	1.0	8
385	Vesiculo-erosive Oral Mucosal Disease Management with Topical Corticosteroids: (1) Fundamental Principles and Specific Agents Available. Journal of Dental Research, 2005, 84, 294-301.	5.2	63
386	Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology, 2006, 54, 1-15.	1.2	893
388	THE EVALUATION OF SEVERAL TOPICAL CORTICOSTEROID PREPARATIONS IN THE BLANCHING TEST. British Journal of Dermatology, 1971, 85, 381-387.	1.5	28
389	Evaluation of the efficacy of topical corticosteroids. British Journal of Dermatology, 2006, 90, 85-90.	1.5	10
390	Halcinonide in the treatment of corticosteroid responsive dermatoses. British Journal of Dermatology, 1974, 90, 435-440.	1.5	14
391	Bio-assay of corticosteroids for topical application. British Journal of Dermatology, 2006, 92, 581-584.	1.5	7
392	A new formulation of 0.1% hydrocortisone cream with vasoconstrictor activity and clinical effectiveness. British Journal of Dermatology, 1975, 92, 585-588.	1.5	20
393	Topical glucocorticoids and suppression of contact sensitivity. A mouse bioassay of anti-inflammatory effects. British Journal of Dermatology, 1985, 112, 539-545.	1.5	5
394	Application of the Food and Drug Administration (FDA) bioequivalent guidance of topical dermatological corticosteroid in yellow-skinned Japanese population: Validation study using a chromameter. Journal of Dermatology, 2006, 33, 684-691.	1.2	7
395	Drugs for asthma. British Journal of Pharmacology, 2006, 147, S297-303.	5.4	95
396	A Review of Atopic Dermatitis. Comprehensive Therapy, 2006, 32, 111-117.	0.2	4

#	ARTICLE	IF	CITATIONS
397	Pig Ear Skin ex Vivo as a Model for in Vivo Dermatopharmacokinetic Studies in Man. Pharmaceutical Research, 2006, 23, 1850-1856.	3.5	160
398	Corticosteroids: The drugs to beat. European Journal of Pharmacology, 2006, 533, 2-14.	3.5	226
399	Topical Treatment with Glucocorticoids. , 2006, , 477-491.		3
400	Systemic sensitivity to corticosteroids in smokers with asthma. European Respiratory Journal, 2006, 29, 64-71.	6.7	45
401	Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. European Respiratory Journal, 2006, 27, 172-187.	6.7	96
402	Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 127-133.	5.6	271
403	Transdermal Penetration Enhancers. Current Drug Therapy, 2007, 2, 133-142.	0.3	4
404	Assessment of Topical Corticosteroid Activity Using the Vasoconstriction Assay in Healthy Volunteers. Skin Pharmacology and Physiology, 2007, 20, 133-140.	2.5	17
405	Topical Bioavailability of Triamcinolone Acetonide: Effect of Occlusion. Skin Pharmacology and Physiology, 2007, 20, 50-56.	2.5	16
407	Inhaled corticosteroids reduce asthma-associated airway hyperperfusion through genomic and nongenomic mechanisms. Pulmonary Pharmacology and Therapeutics, 2007, 20, 157-162.	2.6	14
408	Pharmaceutical Solvents as Vehicles for Topical Dosage Forms. , 2007, , 403-426.		4
409	Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics. , 2007, ,		26
411	Evaluation of the effects of topical clobetasol propionate by visual score, electrical impedance and laser Doppler flowmetry. Skin Research and Technology, 2007, 13, 73-78.	1.6	8
412	Lipid nanoparticles for improved topical application of drugs for skin diseases†. Advanced Drug Delivery Reviews, 2007, 59, 427-443.	13.7	523
413	In Vivo Methods for the Assessment of Topical Drug Bioavailability. Pharmaceutical Research, 2008, 25, 87-103.	3.5	214
414	Topical Corticosteroids, Structure-Activity and the Glucocorticoid Receptor: Discovery and Developmentâ€”A Process of â€œPlanned Serendipityâ€™â€™. Journal of Pharmaceutical Sciences, 2008, 97, 2936-2947.	3.3	37
415	FDA Critical Path Initiatives: Opportunities for Generic Drug Development. AAPS Journal, 2008, 10, 103-109.	4.4	90
416	Topical Therapy in Pediatric Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2008, 27, 161-167.	1.6	17

#	ARTICLE	IF	CITATIONS
417	Bioavailability and bioequivalence of topical glucocorticoids. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 453-466.	4.3	121
418	Modified-Release Drug Delivery Technology. , 0, , .		6
419	Topical Corticosteroids in the Treatment of Acute Sunburn. Archives of Dermatology, 2008, 144, 620-4.	1.4	31
420	Activity of Different Desoximetasone Preparations Compared to Other Topical Corticosteroids in the Vasoconstriction Assay. Skin Pharmacology and Physiology, 2008, 21, 181-187.	2.5	7
421	Management of Atopic Dermatitis in the Pediatric Population. Pediatrics, 2008, 122, 812-824.	2.1	176
422	Bioequivalence assessment of topical clobetasol propionate products using visual and chromametric assessment of skin blanching. Journal of Pharmacy and Pharmaceutical Sciences, 2008, 11, 160.	2.1	13
423	Challenges Encountered in Dermatologic Drug Development. Actas Dermo-sifiliogrÃ¡ficas, 2009, 100, 86-91.	0.4	5
424	Comparison of instruments for investigation of microcirculatory blood flow and red blood cell concentration. Journal of Biomedical Optics, 2009, 14, 034025.	2.6	135
425	Principles of Examination, Investigation and Treatment. , 0, , 34-43.		0
426	Pharmacotherapy of Inflammatory and Pruritic Manifestations of Corticosteroid-Responsive Dermatoses Focus on Clobetasol Propionate. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S1993.	0.4	1
427	The Maximum Pharmacodynamic Effect as a Response Parameter: Pharmacokinetic Considerations. Journal of Pharmacy and Pharmacology, 2010, 51, 999-1008.	2.4	5
428	Low-frequency ultrasound sonophoresis to increase the efficiency of topical steroids: A pilot randomized study of humans. International Journal of Pharmaceutics, 2010, 395, 84-90.	5.2	16
429	Water vapour transmission and occlusivity in vivo of lipophilic excipients used in ointments. International Journal of Cosmetic Science, 2010, 15, 113-124.	2.6	11
430	Targeting abnormal airway vascularity as a therapeutic strategy in asthma. Respiriology, 2010, 15, 459-471.	2.3	15
431	Topical Treatment of Mild to Moderate Psoriasis. Psoriasis Forum, 2010, 16a, 17-25.	0.1	0
432	Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations.. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 11.	2.1	32
433	Hydrocortisone Aceponate Activity and Benefit/Risk Ratio in Relation to Reference Topical Glucocorticoids. Skin Pharmacology and Physiology, 2010, 23, 177-182.	2.5	3
434	How Should Acute Severe Asthma Be Managed in the Intensive Care Unit?. , 2010, , 27-31.		0

#	ARTICLE	IF	CITATIONS
435	Drug Delivery. Handbook of Experimental Pharmacology, 2010, , .	1.8	29
436	Carriers in the Topical Treatment of Skin Disease. Handbook of Experimental Pharmacology, 2010, , 435-468.	1.8	86
437	Correlation of Skin Blanching and Percutaneous Absorption for Glucocorticoid Receptor Agonists by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and Liquid Extraction Surface Analysis with Nanoelectrospray Ionization Mass Spectrometry. Analytical Chemistry, 2010, 82, 7787-7794.	6.5	54
438	Improvement in the percutaneous absorption of beclomethasone dipropionate by β -cyclodextrin complexation. Journal of Pharmacy and Pharmacology, 2011, 37, 532-535.	2.4	44
439	Widespread Use of Toxic Skin Lightening Compounds: Medical and Psychosocial Aspects. Dermatologic Clinics, 2011, 29, 111-123.	1.7	108
440	Dermocorticoides. EMC - Dermatologie, 2011, 45, 1-13.	0.1	0
441	Pulmonary and Nasal Anti-Inflammatory and Anti-Allergy Inhalation Aerosol Delivery Systems. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10, 215-229.	1.1	11
442	The influence of vehicles on skin penetration. Journal of Pharmacy and Pharmacology, 2011, 16, 104T-107T.	2.4	34
443	Quantitative Skin Blanching Assay of Corticosteroid Creams Using Tristimulus Colour Analysis. Journal of Pharmacy and Pharmacology, 2011, 44, 371-378.	2.4	26
444	Evaluation of the percutaneous absorption and metabolism of some aminopropiophenones. Journal of Pharmacy and Pharmacology, 2011, 38, 515-519.	2.4	1
445	The effect of constituents in white soft paraffin on the efficacy of corticosteroid ointments in the vasoconstrictor test. Journal of Pharmacy and Pharmacology, 2011, 23, 253S-254S.	2.4	0
446	BRL 20459, a novel topically active non-steroidal anti-inflammatory drug. Journal of Pharmacy and Pharmacology, 2011, 36, 314-317.	2.4	4
448	Dosage uniformity in hydrocortisone ointment B.P. Journal of Pharmacy and Pharmacology, 2011, 32, 766-772.	2.4	5
449	Bonnes pratiques de l'utilisation des dermocorticoïdes en dermatologie canine. Pratique Medicale Et Chirurgicale De L'Animal De Compagnie, 2011, 46, S1-S21.	0.1	0
450	New Drugs and New Molecular Entities in Dermatology. Archives of Dermatology, 2011, 147, 568.	1.4	14
451	Assessment of topical non-steroidal anti-inflammatory drugs. Journal of Pharmacy and Pharmacology, 2011, 41, 720-722.	2.4	27
452	Comparison of reservoir effect of topical corticosteroids in an experimental animal model by histamine-induced wheal suppression test. Indian Journal of Pharmacology, 2012, 44, 722.	0.7	4
455	Does insulin resistance co-exist with glucocorticoid resistance in the metabolic syndrome? Studies comparing skin sensitivity to glucocorticoids in individuals with and without acanthosis nigricans. Cardiovascular Diabetology, 2012, 11, 31.	6.8	10

#	ARTICLE	IF	CITATIONS
456	Skin-blanching is associated with FEV1, allergy, age and gender in asthma families. Respiratory Medicine, 2012, 106, 1376-1382.	2.9	1
457	Corticosteroid Intravitreal Implants. Developments in Ophthalmology, 2012, 51, 122-133.	0.1	23
458	Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia*. Critical Care Medicine, 2012, 40, 2273-2280.	0.9	31
459	The skinâ€blanching assay. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1197-1202.	2.4	7
460	Brian Barry: Innovative Contributions to Transdermal and Topical Drug Delivery. Skin Pharmacology and Physiology, 2013, 26, 234-242.	2.5	1
461	Solute-Vehicle-Skin Interactions in Percutaneous Absorption: The Principles and the People. Skin Pharmacology and Physiology, 2013, 26, 356-370.	2.5	22
462	Skin Pharmacology. , 2013, , 521-554.		0
463	A Comparative Clinical Evaluation of Once Daily Versus Alternate Day Application of Topical Clobetasol Propionate Cream in Psoriasis. Journal of Clinical and Diagnostic Research JCDR, 2013, 7, 100-5.	0.8	2
464	Airway Pharmacology. , 2013, , 159-183.e9.		1
465	Bioequivalence, Quality, and Novel Assessment Technologies for Topical Products: Current Challenges and Future Prospects. , 2014, , 389-398.		2
466	Glucocorticoids. Chemical Immunology and Allergy, 2014, 100, 311-316.	1.7	57
467	Current Challenges in Bioequivalence, Quality, and Novel Assessment Technologies for Topical Products. Pharmaceutical Research, 2014, 31, 837-846.	3.5	61
468	FDA Bioequivalence Standards. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , .	0.6	14
469	Assessing Topical Bioavailability and Bioequivalence: A Comparison of the In vitro Permeation Test and the Vasoconstrictor Assay. Pharmaceutical Research, 2014, 31, 3529-3537.	3.5	19
470	Dermatotoxicology. , 2014, , 1345-1384.		0
471	PK/TK Analysis of Xenobiotics Absorbed via an Extravascular Route of Administration (Oral) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tt 50		
472	Topical Corticosteroids in Dermatology: From Chemical Development to Galenic Innovation and Therapeutic Trends. Journal of Clinical & Experimental Dermatology Research, 2015, 6, .	0.1	3
473	Recent Advances on Self Modified Patch for (Trans) Dermal Drug Delivery. Recent Patents on Drug Delivery and Formulation, 2015, 9, 88-94.	2.1	3

#	ARTICLE	IF	CITATIONS
475	Tracheobronchial Smooth Muscle Atrophy and Separation. <i>Respiration</i> , 2015, 90, 256-262.	2.6	14
476	Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: In vitro comparison on HaCaT. <i>International Journal of Pharmaceutics</i> , 2015, 479, 422-429.	5.2	31
477	Increased bioavailability of hydrocortisone dissolved in a cream base. <i>Australasian Journal of Dermatology</i> , 2015, 56, e30-4.	0.7	4
478	Survey of International Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products. <i>AAPS Journal</i> , 2015, 17, 121-133.	4.4	22
479	Modern Pharmaceutics, Volume 2. , 0, , .		1
480	Atrophie und Abl�t�sung der tracheobronchialen glatten Muskulatur. <i>Karger Kompass Pneumologie</i> , 2016, 4, 44-50.	0.0	0
481	Lipid nanoparticles for topical application of drugs for skin diseases. , 2016, , 327-361.		6
483	Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1951-1956.	2.4	21
484	Corticosteroid Carboxylic Acid Esters. , 0, , 245-267.		4
485	Advanced topical formulations (ATF). <i>International Journal of Pharmaceutics</i> , 2016, 514, 52-57.	5.2	35
486	Generic Drug Product Development. , 0, , .		1
487	Drug crystallization â�� implications for topical and transdermal delivery. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 817-830.	5.0	56
488	Topical Corticosteroids. , 2017, , 815-830.		0
489	Topical safety and vasoconstrictive assay-based bioequivalence of a new reformulated mometasone cream. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1173-1177.	2.0	1
490	Skin Penetration. , 2017, , 741-755.		3
491	DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 85-91.	3.0	4
492	Dermal Drug Selection and Development. , 2017, , .		7
493	Anti��inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropanone. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1719-1728.	2.4	17

#	ARTICLE	IF	CITATIONS
494	Dermal Absorption of Pesticide Residues. Chemical Research in Toxicology, 2018, 31, 1356-1363.	3.3	8
495	Effect of Delivery Platforms Structure on the Epidermal Antigen Transport for Topical Vaccination. Biomacromolecules, 2018, 19, 4607-4616.	5.4	16
496	The Potential Role of Steroid-Induced Cerebral Vasospasm in the Pathogenesis of Delayed Cerebral Injury in Bacterial Meningitis*. Critical Care Medicine, 2018, 46, 1383-1384.	0.9	2
497	Vasoconstrictor potency of fixed-dose combination calcipotriol (50µg/g) and betamethasone dipropionate (0.5µg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris. Journal of Dermatological Treatment, 2019, 30, 529-533.	2.2	6
498	<p>Current Perspectives on the Management of Infantile Atopic Dermatitis</p>. Journal of Asthma and Allergy, 2020, Volume 13, 563-573.	3.4	8
499	Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert Opinion on Drug Safety, 2020, 19, 423-432.	2.4	8
500	Transdermal delivery systems in cosmetics. Biomedical Dermatology, 2020, 4, .	7.7	48
501	Vesicular Nanocarriers: A Potential Platform for Dermal and Transdermal Drug Delivery. Environmental Chemistry for A Sustainable World, 2021, , 155-209.	0.5	6
502	Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 5-9.	2.4	11
504	A Novel Approach to Assess the Potency of Topical Corticosteroids. Pharmaceutics, 2021, 13, 1456.	4.5	7
505	Assessment of dermal bioavailability: predicting the input function for topical glucocorticoids using stratum corneum sampling. Drug Delivery and Translational Research, 2022, 12, 851-861.	5.8	3
506	Topical Therapy. , 0, , 3965-4016.		4
508	Topische Therapie. , 2005, , 1431-1461.		10
509	Safety Assays in Skin Pharmacology. , 2006, , 365-383.		2
510	The Value of Colloid Dressings in Psoriasis. Advances in Experimental Medicine and Biology, 1999, 455, 377-385.	1.6	2
511	Skin Pharmacology and Dermatology. Developments in Cardiovascular Medicine, 1990, , 141-174.	0.1	13
512	Percutaneous Absorption. , 1993, , 3-15.		1
513	Bioequivalence of Topical Dermatological Products. , 1993, , 393-413.		3

#	ARTICLE	IF	CITATIONS
514	The Human Skin Blanching Assay for Topical Corticosteroid Bioavailability Assessment. , 1993, , 155-162.		2
515	Methods for the Assessment of Bioequivalence of Topical Dosage Forms: Correlations, Optimization Strategies, and Innovative Approaches. , 2014, , 113-151.		4
516	Topical Therapy. , 2009, , 1549-1572.		1
517	Clinical Trial Protocols for Anti-Inflammatory and other Liposome Dermatics. , 1992, , 299-307.		4
518	Vergleich zwischen der vasoconstrictorischen und antientzündlichen Wirkung verschiedener Corticosteroide. , 1968, , 300-304.		2
519	Dermatische Grundlagen und ihre therapeutischen Funktionen. , 2000, , 27-58.		2
520	Anti-Inflammatory Steroids: Mode of Action in Rheumatoid Arthritis and Homograft Reaction. Handbook of Experimental Pharmacology, 1979, , 598-660.	1.8	8
521	Pharmacology of the Microvasculature of the Skin. , 1981, , 379-540.		4
522	Skin Permeability. , 1981, , 541-845.		2
523	The Vasoconstrictor Test as a Model for Developing Topical Formulations. , 1986, , 103-112.		2
524	Colorimetric Evaluation of the Human Skin Blanching Assay. , 1993, , 92-103.		3
525	Topical Therapy. , 2000, , 1719-1746.		2
526	Guidelines for Topical Treatment in Atopic Eczema. , 1991, , 345-355.		5
527	Topical Vehicles: Composition, Principles of Application and Action. , 1991, , 364-374.		3
528	Topical Treatment with Corticosteroids. , 1991, , 375-390.		8
529	Topical Glucocorticoid Therapy in Dermatology. , 2002, , 39-54.		6
530	Topical Corticosteroids: Pharmacology. , 2018, , 11-22.		7
531	Antiinflammatory Steroids. , 1974, , 245-294.		13

#	ARTICLE	IF	CITATIONS
532	The effect of various corticosteroids on the release of β -glucuronidase from human leukocytes challenged with zymosan. British Journal of Dermatology, 1979, 101, 553-556.	1.5	1
533	The effect of topical steroids on cutaneous oxygen tension. British Journal of Dermatology, 1992, 126, 502-504.	1.5	3
534	A comparison of techniques to assess skin blanching following the topical application of glucocorticoids. British Journal of Dermatology, 1996, 134, 837-842.	1.5	25
535	A Reappraisal of Topical Steroid Potency. Pediatrics International, 1996, 13, 239-245.	0.5	1
536	Increased Vasoconstrictor Sensitivity to Glucocorticoids in Essential Hypertension. Hypertension, 1996, 27, 190-196.	2.7	102
537	Bioavailability and Bioequivalence of Dermatological Formulations. Drugs and the Pharmaceutical Sciences, 2002, , 396-493.	0.1	5
538	Penetration Enhancement by Skin Hydration. , 2005, , 67-71.		1
539	Lower Corticosteroid Skin Blanching Response Is Associated with Severe COPD. PLoS ONE, 2014, 9, e91788.	2.5	6
540	The Safe Use of Topical Corticosteroids in Children. Pediatric Annals, 2001, 30, 225-229.	0.8	7
541	Study of reservoir effect of clobetasol propionate cream in an experimental animal model using histamine-induced wheal suppression test. Indian Journal of Dermatology, 2010, 55, 329.	0.3	13
542	Strategies for the Bioequivalence Assessment of Topical Dermatological Dosage Forms. Journal of Bioequivalence & Bioavailability, 2010, 02, .	0.1	11
543	THERAPEUTIC IMPLICATIONS OF PERCUTANEOUS ABSORPTION OF TOPICAL CORTICOSTEROID IN INFANCY AND CHILDHOOD. Medical Journal of Australia, 1971, 2, 315-317.	1.7	1
544	Biological and Pharmacological Tests for the Exploration of Skin Barrier Function. , 2004, , 549-552.		0
545	Treatment of Dermatitis. , 2007, , 21-43.		0
546	Mode of action of glucocorticoids. Series in Dermatological Treatment, 2008, , 165-180.	0.1	2
547	Intracordal Injection of Steroids: Triamcinolone Acetonide. Japan Journal of Logopedics and Phoniatrics, 2010, 51, 179-182.	0.1	0
548	Evaluation of the Effects of Corticosteroids on Histamine Release by in vivo Cutaneous Microdialysis. Journal of Cosmetics Dermatological Sciences and Applications, 2013, 03, 228-233.	0.2	2
549	Bioequivalence for Topical Drug Products. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 335-367.	0.6	0

#	ARTICLE	IF	CITATIONS
550	Challenges in Evaluating Bioequivalence of Topical Dermatological Drug Products. , 2014, , 101-112.		2
551	Clinical Considerations of Bioequivalence for Topical Dermatologic Drugs. , 2014, , 371-377.		0
552	Dermatological Agents. , 1964, , 649-663.		0
553	Topical Corticosteroid Therapy. , 1968, , 277-280.		0
554	Modificaciones clínicas e histológicas de la reacción tuberculínica bajo la acción local del valerato de betametasona en cura oclusiva. , 1968, , 1188-1189.		0
555	LOCAL EFFECTS OF TOPICALLY APPLIED STEROIDS. , 1976, , 717-721.		0
556	Clinical Effects of Betamethasone 17, 21-dipropionate on Eczema. Japanese Journal of Clinical Pharmacology and Therapeutics, 1976, 7, 145-159.	0.1	0
557	Entzündungshemmende Wirkung. , 1982, , 125-147.		0
559	ç«å—çšç´...æ—ã«å³4ã™ã,ã,1ãfãfã,ãf%«è»ÿètã®ãš¹æžœ. Nishinihon Journal of Dermatology, 1984, 46, 357-363.	0.0	0
560	Studies on vasoconstricting action of difluprednate, a new external corticosteroid agent. Comparative studies between occlusive dressing therapy and simple inunction therapy.. Nishinihon Journal of Dermatology, 1985, 47, 1105-1111.	0.0	2
561	What do you do with a Topical Corticosteroid?. , 1985, , 47-60.		0
562	Glukokortikosteroide. , 1985, , 194-216.		0
563	Effects of glucocorticoids on DNA synthesis of normal human skin fibroblasts in early stages of growth. In vitro evaluation of anti-proliferative possibly anti-inflammatory potency of glucocorticoids.. Nishinihon Journal of Dermatology, 1988, 50, 296-302.	0.0	1
564	A critical review of percutaneous penetration studies. , 1988, , 81-89.		0
565	Skin vasoconstriction test of methylprednisolone aceponate (SH440) topical preparations. Comparison with commercial preparations of the same category in healthy volunteers.. Nishinihon Journal of Dermatology, 1991, 53, 328-336.	0.0	1
566	Predictive Assays: Animal and Man, and In Vitro and In Vivo. , 1992, , 703-747.		1
567	Influence of Liposomal Encapsulation on the Activity of a Herbal Non-steroidal Anti-Inflammatory Drug. , 1992, , 329-337.		0
568	Increased Activity and Tolerability of a Conventional Glucocorticoid in a Liposomal Form. , 1992, , 320-328.		0

#	ARTICLE	IF	CITATIONS
569	Influence of Various Topical Liposome Preparations With and Without Active Ingredients on the Cutaneous Blood Flow. , 1992, , 315-319.		0
570	Objektivierung und Quantifizierung von Externa-Wirkungen mittels nicht-invasiver biophysikalischer MeÄYverfahren. , 1993, , 137-147.		0
571	Ethical and Clinical Considerations for Topical Drug Products (Including Surgical Scrubs). , 1993, , 425-429.		0
572	Predictive Assays: Animal and Man, and In Vitro and In Vivo. , 1995, , 703-747.		1
574	Metabolic Fate of MC903 (2). Absorption, Distribution, Metabolism and Excretion after Single Dermal Application in Rats.. Drug Metabolism and Pharmacokinetics, 1996, 11, 81-92.	0.0	1
575	Biological and Pharmacological Tests for the Exploration of Skin Barrier Function. , 2017, , 1115-1118.		0
576	Choosing Topical Drug Candidate: Historical Overview. , 2017, , 15-28.		1
577	Evolution and Development of Topical Corticosteroids. , 2018, , 1-9.		0
578	Rational Use of Topical Corticosteroids. , 2018, , 117-127.		0
579	Topical Side Effects of Topical Corticosteroids. , 2018, , 251-260.		0
580	Two Cases of Laryngeal Injury Due to Endotracheal Intubation that Required Surgical Treatment. Koutou (the LARYNX JAPAN), 2020, 32, 207-212.	0.1	0
581	The Place of Corticosteroids. , 2002, , 757-768.		1
582	Topical Corticosteroids. , 2008, , 561-577.		2
583	Evaluation of the effects of topical clobetasol propionate by electrical impedance. , 2007, , 168-171.		0
584	The Effect of Temperature and Humidity on the Penetration of C14 Acetylsalicylic Acid in Excised Human Skin1. Journal of Investigative Dermatology, 1963, 41, 307-311.	0.7	1
588	What Does Potency Actually Mean for Inhaled Corticosteroids?. Journal of Asthma, 2005, 42, 409-417.	1.7	1
589	The influence of topical steroid application on tuberculin skin reactions in healthy persons. Acta Dermato-Venerologica, 1982, 62, 43-46.	1.3	1
590	Clobetasol propionate (Dermovate) gives new opportunities in the treatment of dermatoses. Vestnik Dermatologii I Venerologii, 2010, 86, 124-134.	0.6	0

#	ARTICLE	IF	CITATIONS
591	Agreement and Correlation Between Different Topical Corticosteroid Potency Classification Systems. JAMA Dermatology, 2022, 158, 796.	4.1	6
593	Topical Corticosteroids. , 2022, , 121-131.		0
594	Topical glucocorticoid application causing iatrogenic Cushingâ€™s syndrome followed by secondary adrenal insufficiency in infants: two case reports. Journal of Medical Case Reports, 2022, 16, .	0.8	1
595	Biological and Pharmacological Tests for the Exploration of Skin Barrier Function. , 2016, , 1-4.		0
596	Biological and Pharmacological Tests for the Exploration of Skin Barrier Function. , 2017, , 1-6.		0
597	The application of corticosteroids for pathological scar prevention and treatment: current review and update. Burns and Trauma, 2023, 11, .	4.9	6
598	Skin Pharmacology. , 2023, , 1-29.		0
599	A Doubleâ€‘Blind Comparison of Quarter Strength Clobetasol Propionate in Unguentum Merck with Betamethasone Valerate in Psoriasis. International Journal of Clinical Practice, 1983, 37, 389-391.	1.7	0
600	Notable Advances in Dermatological Treatment Over the Past Twentyâ€‘five Years. International Journal of Clinical Practice, 1971, 25, 341-352.	1.7	2
601	FLUTICASONE PROPIONATE IN THE TREATMENT OF INFLAMMATORY DERMATOSES. International Journal of Clinical Practice, 1995, 49, 131-133.	1.7	4
602	Impact of Clinical Pharmacology on the Modernization of Drug Development and Regulation. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 165-202.	0.1	0
603	TOPICAL STEROIDS. Clinics in Podiatric Medicine and Surgery, 1992, 9, 285-299.	0.6	0
604	Reverse Iontophoresis: Noninvasive Assessment of Topical Drug Bioavailability. Molecular Pharmaceutics, 0, , .	4.6	0